| Version 2.5.2.0 |
|
|
Abstract
Grant Number: 1R21CA096609-01 Project Title: Genetic Polymorphisms in Myeloma
PI Information: Name Title VAN NESS, BRIAN G. vanne001@umn.edu PROFESSOR AND HEAD Abstract: DESCRIPTION (provided by applicant): Although multiple myeloma is clinically defined as the accumulation of clonal, malignant plasma cells in the bone marrow, the disease shows significant heterogeneity with regard to progression and therapeutic response. The hypothesis addressed in this proposal is that functional genetic polymorphisms are associated with tumor growth control, drug metabolism/detoxification, and DNA repair mechanisms that will influence chemotoxicity and the course of the disease. Cell and DNA banks from 3 phase Ill clinical trials of the Eastern Cooperative Oncology Group will be used to determine allelic frequencies of genetic polymorphisms in genes associated with drug metabolism/transport (cytochrome P450, myeloperoxidase, glutathione S-transferases (M,T,P), multi-drug resistance 1); DNA repair (XRCCC1, ERCC2); and, myeloma related growth factors (lL-6, IL-1b, IL-1RA, IL-10, TNa, Lta, TGFb). Known genetic polymorphisms that alter function of each of these gene products will be correlated with survival, bone disease, toxicity, response, infection, and secondary malignancies. These correlations will provide important genetic markers that will allow better individualized treatment strategies.
Public Health Relevance:
This Public Health Relevance is not available.Thesaurus Terms:
DNA repair, cell growth regulation, drug metabolism, gene frequency, genetic polymorphism, multiple myeloma, neoplasm /cancer genetics
genetic marker, molecular oncology, multidrug resistance, neoplasm /cancer epidemiology
clinical research, human subject
Institution: UNIVERSITY OF MINNESOTA TWIN CITIES 450 MCNAMARA ALUMNI CENTER MINNEAPOLIS, MN 554552070 Fiscal Year: 2002 Department: GENETICS, CELL BIOLOGY & DEVELOPMENT Project Start: 08-JUL-2002 Project End: 30-JUN-2004 ICD: NATIONAL CANCER INSTITUTE IRG: CONC